Literature DB >> 26282891

Crucial role of the orexin-B C-terminus in the induction of OX1 receptor-mediated apoptosis: analysis by alanine scanning, molecular modelling and site-directed mutagenesis.

Pascal Nicole1, Pierre Couvineau1, Nadege Jamin2, Thierry Voisin1, Alain Couvineau1.   

Abstract

BACKGROUND AND
PURPOSE: Orexins (A and B) are hypothalamic peptides that interact with OX1 and OX2 receptors and are involved in the sleep/wake cycle. We previously demonstrated that OX1 receptors are highly expressed in colon cancer tumours and colonic cancer cell lines where orexins induce apoptosis and inhibit tumour growth in preclinical animal models. The present study explored the structure-function relationships of orexin-B and OX1 receptors. EXPERIMENTAL APPROACH: The contribution of all orexin-B residues in orexin-B-induced apoptosis was investigated by alanine scanning. To determine which OX1 receptor domains are involved in orexin-B binding and apoptosis, a 3D model of OX1 receptor docked to the orexin-B C-terminus (AA-20-28) was developed. Substitution of residues present in OX1 receptor transmembrane (TM) domains by site-directed mutagenesis was performed. KEY
RESULTS: Alanine substitution of orexin-B residues, L(11) , L(15) , A(22) , G(24) , I(25) , L(26) and M(28) , altered orexin-B's binding affinity. Substitution of these residues and of the Q(16) , A(17) , S(18) , N(20) and T(27) residues inhibited apoptosis in CHO-S-OX1 receptor cells. The K(120) , P(123) , Y(124) , N(318) , K(321) , F(340) , T(341) , H(344) and W(345) residues localized in TM2, TM3, TM6 and TM7 of OX1 receptors were shown to play a role in orexin-B recognition and orexin-B/OX1 receptor-induced apoptosis. CONCLUSIONS AND IMPLICATIONS: The C-terminus of orexin-B (i) plays an important role in its pro-apoptotic effect; and (ii) interacts with some residues localized in the OX1 receptor TM. This study defines the structure-function relationship for orexin-B recognition by human OX1 receptors and orexin-B/OX1 receptor-induced apoptosis, an important step for the future development of new agonist molecules.
© 2015 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26282891      PMCID: PMC4687804          DOI: 10.1111/bph.13287

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

1.  Development of an orexin-2 receptor selective agonist, [Ala(11), D-Leu(15)]orexin-B.

Authors:  Shuichi Asahi; Shin-Ichiro Egashira; Masao Matsuda; Hisashi Iwaasa; Akio Kanatani; Mitsuru Ohkubo; Masaki Ihara; Hajime Morishima
Journal:  Bioorg Med Chem Lett       Date:  2003-01-06       Impact factor: 2.823

2.  The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling.

Authors:  Konstantin Arnold; Lorenza Bordoli; Jürgen Kopp; Torsten Schwede
Journal:  Bioinformatics       Date:  2005-11-13       Impact factor: 6.937

3.  Solution structure of a new hypothalamic neuropeptide, human hypocretin-2/orexin-B.

Authors:  J H Lee; E Bang; K J Chae; J Y Kim; D W Lee; W Lee
Journal:  Eur J Biochem       Date:  1999-12

4.  Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types.

Authors:  Jeffery B Klauda; Richard M Venable; J Alfredo Freites; Joseph W O'Connor; Douglas J Tobias; Carlos Mondragon-Ramirez; Igor Vorobyov; Alexander D MacKerell; Richard W Pastor
Journal:  J Phys Chem B       Date:  2010-06-17       Impact factor: 2.991

Review 5.  International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology.

Authors:  Anthony L Gotter; Andrea L Webber; Paul J Coleman; John J Renger; Christopher J Winrow
Journal:  Pharmacol Rev       Date:  2012-07       Impact factor: 25.468

6.  Crucial role of the orexin-B C-terminus in the induction of OX1 receptor-mediated apoptosis: analysis by alanine scanning, molecular modelling and site-directed mutagenesis.

Authors:  Pascal Nicole; Pierre Couvineau; Nadege Jamin; Thierry Voisin; Alain Couvineau
Journal:  Br J Pharmacol       Date:  2015-09-30       Impact factor: 8.739

7.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

8.  Orexins acting at native OX(1) receptor in colon cancer and neuroblastoma cells or at recombinant OX(1) receptor suppress cell growth by inducing apoptosis.

Authors:  Patricia Rouet-Benzineb; Christiane Rouyer-Fessard; Anne Jarry; Virgile Avondo; Cécile Pouzet; Masashi Yanagisawa; Christian Laboisse; Marc Laburthe; Thierry Voisin
Journal:  J Biol Chem       Date:  2004-08-13       Impact factor: 5.157

9.  A hallmark of immunoreceptor, the tyrosine-based inhibitory motif ITIM, is present in the G protein-coupled receptor OX1R for orexins and drives apoptosis: a novel mechanism.

Authors:  Thierry Voisin; Aadil El Firar; Christiane Rouyer-Fessard; Valérie Gratio; Marc Laburthe
Journal:  FASEB J       Date:  2008-01-15       Impact factor: 5.191

10.  The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands.

Authors:  Adam J Pawson; Joanna L Sharman; Helen E Benson; Elena Faccenda; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Christopher Southan; Michael Spedding; Wenyuan Yu; Anthony J Harmar
Journal:  Nucleic Acids Res       Date:  2013-11-14       Impact factor: 16.971

View more
  7 in total

1.  Crucial role of the orexin-B C-terminus in the induction of OX1 receptor-mediated apoptosis: analysis by alanine scanning, molecular modelling and site-directed mutagenesis.

Authors:  Pascal Nicole; Pierre Couvineau; Nadege Jamin; Thierry Voisin; Alain Couvineau
Journal:  Br J Pharmacol       Date:  2015-09-30       Impact factor: 8.739

2.  Impact of Orexin-A Treatment on Food Intake, Energy Metabolism and Body Weight in Mice.

Authors:  Anne Blais; Gaëtan Drouin; Catherine Chaumontet; Thierry Voisin; Anne Couvelard; Patrick Christian Even; Alain Couvineau
Journal:  PLoS One       Date:  2017-01-13       Impact factor: 3.240

3.  In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma.

Authors:  Stéphanie Dayot; Daniela Speisky; Anne Couvelard; Pierre Bourgoin; Valérie Gratio; Jérôme Cros; Vinciane Rebours; Alain Sauvanet; Pierre Bedossa; Valérie Paradis; Philippe Ruszniewski; Alain Couvineau; Thierry Voisin
Journal:  Oncotarget       Date:  2018-01-09

Review 4.  The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role.

Authors:  Alain Couvineau; Stéphanie Dayot; Pascal Nicole; Valérie Gratio; Vinciane Rebours; Anne Couvelard; Thierry Voisin
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-27       Impact factor: 5.555

Review 5.  Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases.

Authors:  Alain Couvineau; Thierry Voisin; Pascal Nicole; Valérie Gratio; Catalina Abad; Yossan-Var Tan
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-22       Impact factor: 5.555

Review 6.  Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions.

Authors:  Alain Couvineau; Thierry Voisin; Pascal Nicole; Valerie Gratio; Anne Blais
Journal:  World J Gastroenterol       Date:  2021-11-28       Impact factor: 5.742

Review 7.  The Orexin receptors: Structural and anti-tumoral properties.

Authors:  Alain Couvineau; Pascal Nicole; Valérie Gratio; Thierry Voisin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-28       Impact factor: 6.055

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.